We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GENERIC OXYCONTIN NEEDS RISK MANAGEMENT PLAN, PURDUE SAYS
Purdue Pharma has petitioned the FDA to withhold final approval for a version of its profitable pain drug OxyContin until generic firms implement appropriate risk management plans (RMPs) — a move that could delay generic competition.